Richard M Stone

Richard M Stone

UNVERIFIED PROFILE

Are you Richard M Stone?   Register this Author

Register author
Richard M Stone

Richard M Stone

Publications by authors named "Richard M Stone"

Are you Richard M Stone?   Register this Author

100Publications

2718Reads

-Profile Views

Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies.

J Am Geriatr Soc 2019 May 4;67(5):889-897. Epub 2019 Apr 4.

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgs.15835DOI Listing
May 2019

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.

Cell 2019 Mar 28;176(6):1265-1281.e24. Epub 2019 Feb 28.

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Ludwig Center at Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00928674193009
Publisher Site
http://dx.doi.org/10.1016/j.cell.2019.01.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515904PMC
March 2019

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Cancer 2018 Dec 5;124(24):4601-4609. Epub 2018 Oct 5.

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31769
Publisher Site
http://dx.doi.org/10.1002/cncr.31769DOI Listing
December 2018

What FLT3 inhibitor holds the greatest promise?

Authors:
Richard M Stone

Best Pract Res Clin Haematol 2018 12 20;31(4):401-404. Epub 2018 Sep 20.

Director, Adult Leukemia Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, D2053, Boston, MA, 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2018.09.008DOI Listing
December 2018

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

N Engl J Med 2018 12 1;379(26):2517-2528. Epub 2018 Dec 1.

From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); Stanford University School of Medicine, Stanford (S.C.), and the City of Hope Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1812836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325637PMC
December 2018

Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not apply.

Haematologica 2018 Nov;103(11):1758-1759

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.201848DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278980PMC
November 2018

The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence.

Gynecol Oncol 2018 11;151(2):187-189

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.10.013DOI Listing
November 2018

Application of multi-state models in cancer clinical trials.

Clin Trials 2018 Oct 23;15(5):489-498. Epub 2018 Jul 23.

1 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774518789098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133743PMC
October 2018

Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema.

J Neuropathol Exp Neurol 2018 Oct;77(10):877-882

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/nly064DOI Listing
October 2018

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

J Clin Oncol 2018 Sep 19;36(26):2684-2692. Epub 2018 Jul 19.

Jeffrey E. Lancet, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Geoffrey L. Uy, Washington University School of Medicine, St Louis, MO; Jorge E. Cortes, The University of Texas MD Anderson Cancer Center, Houston, TX; Laura F. Newell, Oregon Health & Science University, Portland, OR; Tara L. Lin, University of Kansas Medical Center, Kansas City, KS; Ellen K. Ritchie, Weill Cornell Medical College, New York; Jonathan E. Kolitz, Northwell Health System, Lake Success; Daniel H. Ryan, University of Rochester, Rochester, NY; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; Stephen A. Strickland, Vanderbilt-Ingram Cancer Center, Nashville, TN; Donna Hogge, Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada; Scott R. Solomon, The Leukemia Program at Northside Hospital Cancer Center Institute, Atlanta, GA; Richard M. Stone, Dana-Farber Cancer Institute, Boston, MA; Dale L. Bixby, University of Michigan, Grass Lake, MI; Gary J. Schiller, University of California-Los Angeles, Los Angeles; Matthew J. Wieduwilt, University of California-San Diego, La Jolla; Kamalika Banerjee, Michael Chiarella, Arthur C. Louie, Jazz Pharmaceuticals, Palo Alto; Bruno C. Medeiros, Stanford University School of Medicine, Stanford, CA; and Antje Hoering, Cancer Research and Biostatistics, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025PMC
September 2018

Location, Location, Location: Mutant NPM1c Cytoplasmic Localization Is Required to Maintain Stem Cell Genes in AML.

Cancer Cell 2018 Sep;34(3):355-357

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.08.013DOI Listing
September 2018

Single 6-mg dose of rasburicase: The experience in a large academic medical center.

J Oncol Pharm Pract 2018 Aug 15:1078155218791333. Epub 2018 Aug 15.

1 Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155218791333DOI Listing
August 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med 2018 Jun 2;378(25):2386-2398. Epub 2018 Jun 2.

From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) - both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.); University of Texas Southwestern Medical Center, Dallas (R.H.C.); University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco (G.N.M.), and City of Hope Medical Center, Duarte (A.S.S.) - both in California; University of Colorado School of Medicine, Aurora (D.A.P.); Sarah Cannon Research Institute, Nashville (W.D.); Massachusetts General Hospital Cancer Center (A.T.F.) and Dana-Farber Cancer Institute (R.M.S.), Boston, and Agios Pharmaceuticals, Cambridge (S.C., H.W., V.Z., K.E.Y., S.M.K., H.Y., D.D., B.F., M.G., H.L., S.A., B.W., E.C.A.) - all in Massachusetts; University of Alabama at Birmingham, Birmingham (H.P.E.); Johns Hopkins University, Baltimore (G.T.P.); Washington University School of Medicine, St. Louis (G.L.U.); Mayo Clinic, Jacksonville, FL (J.M.F.); Oregon Health and Science University Knight Cancer Institute, Portland (E.T.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.K.S.); Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Mayo Clinic, Phoenix, AZ (J.L.S.); and Cleveland Clinic, Cleveland (M.A.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1716984DOI Listing
June 2018

A concise review of BCL-2 inhibition in acute myeloid leukemia.

Expert Rev Hematol 2018 02 3;11(2):145-154. Epub 2018 Jan 3.

b Dana Farber Cancer Institute , Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1420474DOI Listing
February 2018

Novel Therapeutics in Acute Myeloid Leukemia.

Am Soc Clin Oncol Educ Book 2017 ;37:495-503

From the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Stanford University School of Medicine, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EDBK_175401DOI Listing
December 2017

Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?

Authors:
Richard M Stone

Best Pract Res Clin Haematol 2017 12 22;30(4):312-316. Epub 2017 Sep 22.

Harvard Medical School, Boston, MA 02215, USA; Adult Leukemia Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, D2053, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2017.09.006DOI Listing
December 2017

Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.

N Engl J Med 2017 11;377(19):1903

University Hospital of Ulm, Ulm, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1711340DOI Listing
November 2017

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

J Clin Oncol 2017 Aug 9;35(24):2745-2753. Epub 2017 May 9.

Mikkael A. Sekeres and Aziz Nazha, Cleveland Clinic, Cleveland; Clara D. Bloomfield, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Megan Othus and Anna Moseley, SWOG Statistical Center; Min Fang and Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center, Seattle, WA; Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Olatoyosi Odenike, University of Chicago, Chicago; Mario R. Velasco, Heartland NCORP/Cancer Care Specialists of Central Illinois, Decatur, IL; Richard M. Stone, Dana Farber Cancer Institute; Eyal C. Attar, Massachusetts General Hospital, Boston, MA; Steven D. Gore, Yale University, New Haven, CT; Mark R. Litzow, Mayo Clinic, Rochester, MN; Rena Buckstein, Sunnybrook Health Sciences Centre, Toronto; Elina K. Cook, Alyssa H. Cull, and Michael J. Rauh, Queen's University, Kingston, Ontario, Canada; Diane Roulston, University of Michigan, Ann Arbor, MI; Yanming Zhang, Memorial Sloan-Kettering Cancer Center, New York, NY; Rakesh Gaur, Kansas City National Cancer Institute Community Oncology Research Program, Prairie Village, KS; Ehab Atallah, Medical College of Wisconsin, Milwaukee, WI; and Harry P. Erba, University of Alabama, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562170PMC
August 2017

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

N Engl J Med 2017 08 23;377(5):454-464. Epub 2017 Jun 23.

From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (R.M.S.); the Division of Biomedical Statistics and Informatics (S.J.M., K.L.) and the Alliance Statistics and Data Center (S.J.M., K.L., S.G.), Mayo Clinic, Rochester, MN; the Alliance Statistics and Data Center, Duke University, Durham, NC (B.L.S.); the Ohio State University Comprehensive Cancer Center, Columbus (S.G., C.D.B., T.W.P., G.M., R.B.K.); Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden (C.T., G.E.), Department of Internal Medicine III, University Hospital of Ulm, Ulm (K.D., R.F.S., H.D.), Hematology and Oncology, University of Leipzig, Leipzig (D.N.), Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover (J.K., A.G.), and Department of Medicine II, Hematology-Oncology, Goethe University Hospital Frankfurt, Frankfurt am Main (H.S.) - all in Germany; the Department of Biomedicine and Prevention, University Tor Vergata, Rome (F.L.-C., S.A.); the Department of Clinical Haematology, Alfred Hospital and Monash University, Melbourne, VIC, Australia (A.W.); Hospital de la Santa Creu i Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona (J.S.), and Hospital Universitario la Fe, Hematology Department, Department of Medicine, University of Valencia, Valencia (M.A.S.) - both in Spain; the Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto (J.M.B.); Radboud Institute Molecular Studies, Radboud University Medical Center, Nijmegen, the Netherlands (T.W.); the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (F.R.A.); the Division of Hematology-Oncology, Stanford Comprehensive Cancer Center, Stanford University, Stanford, CA (B.C.M.); the Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.S.T.); and the Department of Medicine, University of Chicago, Chicago (R.A.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1614359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754190PMC
August 2017

The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.

Hematol Oncol Clin North Am 2017 08 17;31(4):663-680. Epub 2017 May 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Dana 2058, Boston, MA 02215-5450, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2017.03.002DOI Listing
August 2017

Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?

J Oncol Pract 2017 08;13(8):471-480

Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.021675DOI Listing
August 2017

Calcium Pyrophosphate Crystal Inflammatory Arthritis (Pseudogout) with Myelodysplastic Syndrome: A New Paraneoplastic Syndrome?

J Rheumatol 2017 07;44(7):1101-1102

Brigham and Women's Hospital and Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016375PMC
July 2017

Self-reported sleep disturbance and survival in myelodysplastic syndromes.

Br J Haematol 2017 05 8;177(4):562-566. Epub 2017 Mar 8.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14573DOI Listing
May 2017

Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy.

Curr Opin Hematol 2017 03;24(2):139-145

aLeukemia Service, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel bDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000322DOI Listing
March 2017

3 + 7 + FLT3 inhibitors: 1 + 1 ≠ 2.

Authors:
Richard M Stone

Blood 2017 03;129(9):1061-1062

DANA-FARBER CANCER INSTITUTE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-12-754473DOI Listing
March 2017

Thrombosis in AML? Yes, but when to worry?

Authors:
Richard M Stone

Blood 2016 10;128(14):1784-1785

DANA-FARBER CANCER INSTITUTE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-08-734715DOI Listing
October 2016

Should older adults with AML receive post-remission therapy?

Authors:
Richard M Stone

Best Pract Res Clin Haematol 2015 Jun-Sep;28(2-3):106-11. Epub 2015 Oct 20.

Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D-2053, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2015.10.007DOI Listing
September 2016

The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia.

Leuk Lymphoma 2016 08 22;57(8):1977-9. Epub 2016 Mar 22.

c Bone Marrow Transplant Unit, Massachusetts General Hospital , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2016.1161188DOI Listing
August 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 07 11;30(1):183. Epub 2016 Jul 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.008DOI Listing
July 2016

Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes.

Br J Haematol 2016 06 23;173(5):713-21. Epub 2016 Feb 23.

Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13987DOI Listing
June 2016

Transplantation after Remission in Mixed Phenotype Acute Leukemia: A Good Idea.

Authors:
Richard M Stone

Biol Blood Marrow Transplant 2016 06 14;22(6):971-972. Epub 2016 Apr 14.

Adult Leukemia Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.04.001DOI Listing
June 2016

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2016 06 29;16(6):341-349.e1. Epub 2016 Mar 29.

Department of Oncology, Hematology, and Cell Therapy, Centre Hospitalier Universitaire de Poitiers, Clinical Investigation Center, Inserm 0802, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.03.004DOI Listing
June 2016

Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis.

Lancet Haematol 2016 Jun 18;3(6):e276-83. Epub 2016 May 18.

Bone Marrow Transplant Program, Department of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(16)30024-2DOI Listing
June 2016

Targeting MTHFD2 in acute myeloid leukemia.

J Exp Med 2016 06 20;213(7):1285-306. Epub 2016 Jun 20.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215 Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215 Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20151574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925018PMC
June 2016

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.

ACS Med Chem Lett 2016 May 8;7(5):476-81. Epub 2016 Mar 8.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Avenue, Longwood Center LC-2209, Boston, Massachusetts 02115, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.5b00498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867484PMC
May 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 04;29(4):574-586

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177991PMC
April 2016

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.

J Clin Oncol 2015 Dec 2;33(35):4167-75. Epub 2015 Nov 2.

Steven M. Devine and William Blum, Ohio State University, Columbus, OH; Kouros Owzar, Flora Mulkey, Vera Hars, and Alexander B. Sibley, Alliance Statistics and Data Center, Duke University, Durham; Thomas C. Shea, University of North Carolina, Chapel Hill, NC; Richard M. Stone, Robert J. Soiffer, and Edwin P. Alyea, Dana-Farber Cancer Institute; Yi-Bin Chen, Massachusetts General Hospital, Boston, MA; Jack W. Hsu, University of Florida, Gainesville, FL; Richard E. Champlin, MD Anderson Cancer Research Center, Houston, TX; Ravi Vij, Washington University, St. Louis, MO; James Slack, Mayo Clinic, Scottsdale, AZ; Richard A. Larson, University of Chicago, Chicago, IL; Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, NY; Shelly Carter, The EMMES Corporation, Bethesda, MD; Mary M. Horowitz, Medical College of Wisconsin, Milwaukee, WI; and Charles Linker, University of California at San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.7273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658453PMC
December 2015

Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.

Clin Cancer Res 2015 Oct 17;21(19):4262-9. Epub 2015 Aug 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0125DOI Listing
October 2015

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

N Engl J Med 2015 Oct 9;373(18):1733-47. Epub 2015 Sep 9.

From the Institute of Hematology, Department of Medicine, and Centro di Ricerca Emato-Oncologico (CREO), University of Perugia, and Ospedale Santa Maria della Misericordia, Perugia (E.T., L.D.C., F.F., S.A., M.C., M.P.M., B.F.), the Department of Experimental, Diagnostic, and Specialty Medicine, Units of Hematology and Hematopathology, Bologna University School of Medicine, Bologna (A.B., S.A.P., P.L.Z.), Hematology Unit, Centro Trapianti e Terapie Cellulari Carlo Melzi, Dipartimento di Science Mediche Sperimentali e Cliniche, Azienda Ospedaliero Universitaria, Udine (F.Z.), the Department of Cellular Biotechnologies and Hematology, Division of Hematology, Sapienza University, Rome (A.P., R.F.), the Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Regionale San Carlo, Potenza (M.C.), the Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara (D.R.), Hematology Unit, Ospedale Ferrarotto, Catania (G.M.), the Department of Onco-Hematology, Fondazione IRCCS, Policlinico San Matteo, Pavia (M.V.), Hematology Unit, Spedali Civili, Brescia (A. Anastasia), the Department of Medicine, Section of Hematology, University of Verona, Verona (A. Ambrosetti), Onco-Hematology Unit, Fondazione di Ricerca e Cura S.S. Giovanni Paolo II, Campobasso (V.F.), Institute of Hematology 1, IRCCS, Azienda Ospedaliero Universitaria San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genoa (A.M.C.), the Department of Hematology, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona (P.L.), and the Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (A.R.) - all in Italy; Leukemia Service (J.H.P., S.S.C., R.L.L., O.A-W., M.S.T.,) and Dermatology Service (M.E.L.), the Department of Medicine, Human Oncology and Pathogenesis Program (S.S., Y.R.C., E.K., R.L.L., C.Y.P., M.F.B., O.A-W.), the Departments of Epidemiology and Biostatistics (S.D.), Pathology (C.Y.P.), and Pharmaco

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1506583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811324PMC
October 2015

Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing.

Exp Hematol Oncol 2015 8;4:30. Epub 2015 Oct 8.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-015-0026-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599757PMC
October 2015

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

Leuk Res 2015 Sep 9. Epub 2015 Sep 9.

Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2015.09.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016250PMC
September 2015

Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia.

Mod Pathol 2015 Jul 15;28(7):965-76. Epub 2015 May 15.

Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/modpathol201555
Publisher Site
http://dx.doi.org/10.1038/modpathol.2015.55DOI Listing
July 2015

Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.

J Geriatr Oncol 2015 Jul 11;6(4):288-98. Epub 2015 Jun 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States; Geriatric Research Education and Clinical Center, VA Boston Medical Center, Boston, MA, United States; Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2015.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860010PMC
July 2015

Myelodysplastic syndromes, version 2.2015.

J Natl Compr Canc Netw 2015 Mar;13(3):261-72

From Stanford Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; UC San Diego Moores Cancer Center; University of Rochester Medical Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Duke Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Massachusetts General Hospital Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Roswell Park Cancer Institute; Vanderbilt-Ingram Cancer Center; Memorial Sloan Kettering Cancer Center; Moffitt Cancer Center; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; University of Colorado Cancer Center; Huntsman Cancer Institute at the University of Utah; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696005PMC
March 2015